Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: Did zoledronic acid trigger osteoblastic activity and avid calcium uptake?

Clinical Genitourinary Cancer

Volumn 10, Issue 1, 2012, Pages 50-53

  Ho, Joon Wee ^a   Sundar, Santhanam ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Bisphosphonates; Hypocalcemia; Osteoblastic metastases; Prostate cancer

Indexed keywords

CALCICHEW D3; CALCIUM; CYPROTERONE; DECAPEPTYK SR; DOCETAXEL; GLUCONATE CALCIUM; PROSTATE SPECIFIC ANTIGEN; TRIPTORELIN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

AGED; ARTICLE; BONE DEVELOPMENT; BONE METASTASIS; BONE PAIN; CALCIUM BLOOD LEVEL; CALCIUM TRANSPORT; CASE REPORT; DIGITAL RECTAL EXAMINATION; DISEASE FREE INTERVAL; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HORMONE RESISTANCE; HUMAN; HYPOCALCEMIA; LABORATORY TEST; MALE; OSTEOBLAST; PROSTATE CANCER; PROSTATE CARCINOMA; RISK ASSESSMENT; TREATMENT INDICATION; URINARY FREQUENCY; URINARY HESITANCY;

AGED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CALCIUM; DIPHOSPHONATES; HUMANS; HYPOCALCEMIA; IMIDAZOLES; MALE; OSTEOBLASTS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84857215400     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2011.11.004     Document Type: Article

References (21)

1. J.J. Body Rational for the use of bisphosphonates in osteoblastic and osteolytic bone lesions Breast Suppl 2 2003 s37 s44
2. T.E. Keller, J. Brown Prostate cancer bone metastases promote both osteolytic and osteoblastic activity J Cell Biochem 91 2004 718 729
3. Cancer Research UK Prostate cancer statistics: key facts http://www.info.cancerresearchuk.org/prod-consump/groups/cr-common/@nre/@sta/ documents/generalcontent/crukmig-1000ast-3088.pdf November 2010 Accessed: January 16, 2011
4. F. Saad, D. Gleason, R. Murray Long term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst 96 2004 879 882 (Pubitemid 38807610)
5. C. Champallou, J. Basuyau, C. Veyret Hypocalcaemia following pamidronate administration for bone metastases for solid tumour: three clinical case reports J Pain Symptom Manageme 25 2003 185 190 (Pubitemid 36183296)
6. T. Breen, E. Shane Prolonged hypocalcaemia after treatment with zoledronic acid in a patient with prostate cancer and vitamin D deficiency J Clin Oncol 22 2004 1531 1532 (Pubitemid 41103642)
7. J. Gulley, S. Wu, P. Arlen Zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases Clin Genitourin Cancer 5 2007 403 405 (Pubitemid 47584479)
8. Zometa ©: summary of product characteristics. 2010. Novartis [Web site] http://www.zometa.com/around-the-world/european-product-characteristics. jsp# Accessed: January 16, 2011
9. S. Chennuru, J. Koduri, M.A. Baumann Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid Intern Med J 38 2008 635 637
10. M. Zuradelli, G. Masci, G. Biancafiore High incidence of hypocalcaemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid. s.l Oncologist 14 2009 548 556
11. H. Miho, T. Iwamoto, N. Soga Risk factors contributing to the development of hypocalcemia after zoledronic acid administration in patients with bone metastases of solid tumour Biol Pharm Bull 33 2010 721 724
12. R.M.L. Murray, V. Grill, N. Crinis Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostate cancer J Clin Endocrinol Metabol 86 2001 4133 4138 (Pubitemid 32848525)
13. M.I. Fokkema, L.J.M. de Heide, W.D. van Schelven Severe hypocalcaemia associated with extensive osteoblastic metastases in a patient with prostate cancer Netherlands J Med 63 2005 34 37 (Pubitemid 40214678)
14. S.C. Lim, C.E. Tan, T.C. Aw A man with osteoblastic metastasis and hypocalcaemia Singapore Med J 41 2000 74 76 (Pubitemid 30160946)
15. M. Szentirmai Hypocalcaemia due to avid calcium uptake by osteoblastic metastases of prostate cancer West J Med 163 1995 577 578 (Pubitemid 26302972)
16. S. Yener, O. Demir, O. Ozdogan Severe hypocalcaemia because of osteoblastic prostate carcinoma metastases Int J Clin Pract 62 2008 1630 1631
17. G. Im, S. Qureshi, J. Kenney Osteoblast proliferation and maturation by bisphosphonates Biomaterials 25 2004 4105 4115 (Pubitemid 38388576)
18. F.P. Koch, S.S. Yekta, C. Merkel The impact of bisphosphonates on the osteoblast proliferation and collagen gene expression in vitro Head Face Med 6 2010 12
19. E. Corey, L.G. Brown, J.E. Quinn Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer Clin Cancer Res 9 2003 295 306 (Pubitemid 36109746)
20. Y.P. Lee, E.D. Schwarz, M. Davies Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe combined immunodeficient mouse model Cancer Res 62 2002 5564 5570
21. C. Ryan, D. Huo, L. Demers Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer J Urol 176 2006 972 978 (Pubitemid 44142571)